Weiguo Ye Sells 9,400 Shares of Gyre Therapeutics (NASDAQ:GYRE) Stock

Gyre Therapeutics, Inc. (NASDAQ:GYRE) COO Weiguo Ye sold 9,400 shares of the stock in a transaction on Wednesday, May 20th. The stock was sold at an average price of $6.15, for a total value of $57,810.00. Following the completion of the transaction, the chief operating officer directly owned 700,000 shares of the company’s stock, valued at approximately $4,305,000. The trade was a 1.33% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website.

Weiguo Ye also recently made the following trade(s):

• On Thursday, May 21st, Weiguo Ye sold 12,820 shares of Gyre Therapeutics stock. The stock was sold at an average price of $6.15, for a total value of $78,843.00.

Gyre Therapeutics Stock Performance

NASDAQ:GYRE opened at $6.06 on Friday. Gyre Therapeutics, Inc. has a 1 year low of $5.97 and a 1 year high of $11.61. The stock has a market cap of $588.00 million, a price-to-earnings ratio of -67.33 and a beta of 2.03. The business has a fifty day moving average of $7.24 and a 200-day moving average of $7.60.

Gyre Therapeutics (NASDAQ:GYRE) last released its quarterly earnings results on Thursday, March 12th. The company reported $0.04 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.08 by ($0.04). Gyre Therapeutics had a positive return on equity of 3.13% and a negative net margin of 5.44%.The business had revenue of $37.20 million during the quarter, compared to the consensus estimate of $36.30 million. On average, equities research analysts predict that Gyre Therapeutics, Inc. will post -0.3 EPS for the current year.

Analyst Ratings Changes

GYRE has been the subject of several recent analyst reports. Wall Street Zen cut Gyre Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 16th. Weiss Ratings cut Gyre Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a research note on Monday, May 11th. Finally, Zacks Research cut Gyre Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Monday, March 16th. Two research analysts have rated the stock with a Buy rating and two have issued a Sell rating to the stock. According to MarketBeat, Gyre Therapeutics currently has a consensus rating of “Hold” and an average target price of $17.00.

Institutional Trading of Gyre Therapeutics

Institutional investors have recently modified their holdings of the company. Alliancebernstein L.P. lifted its holdings in shares of Gyre Therapeutics by 9.5% in the third quarter. Alliancebernstein L.P. now owns 21,830 shares of the company’s stock valued at $163,000 after buying an additional 1,900 shares during the period. Barclays PLC lifted its holdings in shares of Gyre Therapeutics by 38.3% in the fourth quarter. Barclays PLC now owns 18,531 shares of the company’s stock valued at $131,000 after buying an additional 5,135 shares during the period. Lazard Asset Management LLC acquired a new stake in shares of Gyre Therapeutics in the third quarter valued at $111,000. Wells Fargo & Company MN lifted its holdings in shares of Gyre Therapeutics by 132.4% in the fourth quarter. Wells Fargo & Company MN now owns 12,919 shares of the company’s stock valued at $91,000 after buying an additional 7,361 shares during the period. Finally, Bank of America Corp DE lifted its holdings in shares of Gyre Therapeutics by 40.4% in the fourth quarter. Bank of America Corp DE now owns 6,937 shares of the company’s stock valued at $84,000 after buying an additional 1,996 shares during the period. Institutional investors and hedge funds own 23.99% of the company’s stock.

About Gyre Therapeutics

Gyre Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing small-molecule therapies that target lipid biology to treat a range of metabolic, inflammatory and neurodegenerative diseases. The company’s proprietary platform combines lipidomic profiling with drug discovery tools to identify compounds that selectively modulate membrane lipid composition and restore normal protein function in disease-relevant cells.

Gyre’s preclinical pipeline includes programs in nonalcoholic steatohepatitis (NASH), Alzheimer’s disease and autoimmune conditions, reflecting its strategy of applying a unified lipid-targeted approach across multiple therapeutic areas.